Blog

Vigil Immunotherapy Tolerated Well for Recurrent Ovarian CA Tx – Monthly Prescribing Reference

Vigil Immunotherapy Tolerated Well for Recurrent Ovarian CA Tx
Monthly Prescribing Reference
HealthDay News — Vigil immunotherapy shows good tolerability for recurrent ovarian cancer patients, and PARP 7, a poly(ADP-ribose) polymerase protein, may play a significant role in survival for ovarian cancer, according to two studies presented at

and more »

2018-03-27 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.